Literature DB >> 12458888

Predominant apolipoprotein J exists as lipid-poor mixtures in cerebrospinal fluid.

Takefumi Suzuki1, Minoru Tozuka, Yamauchi Kazuyoshi, Mitsutoshi Sugano, Tetsuo Nakabayashi, Nobuo Okumura, Hiroya Hidaka, Tsutomu Katsuyama, Keiichi Higuchi.   

Abstract

Apolipoprotein (apo) J, abundant in cerebrospinal fluid (CSF), is known to play a role in the pathogenesis of Alzheimer's disease (AD); however, the mechanism remains obscure. To characterize the apoJ-containing lipoproteins in CSF, we compared the distribution of apoJ in CSF lipoprotein partides with those of apoE and apoAI. CSF lipoproteins (fractionated by ultracentrifugation, gel-filtration chromatography, and agarose-gel electrophoresis) were characterized by immunoblot analysis using anti-apoJ, anti-apoE, and anti-apoAI antibodies. Immunoprecipitation and immunoabsorption were used to clarify the combinations in which these apolipoproteins exist. All of the apoJ in CSF was in the fraction with density of > or = 1.250 g/ml after ultracentrifugation; relatively little apoE and apoAI was in that fraction. In gel-filtration chromatography, the main peak of apoJ-containing lipoprotein particles was clearly distinguishable from those of apoE- and apoAI-containing lipoproteins. Immunoabsorption and agarose-gel electrophoresis indicated that the dominant apoJ-containing lipoprotein partides did not contain apoE. These findings indicate that a significant fraction of the apoJ present in CSF does not co-exist with apoE or apoAI within the same particles. Immunoprecipitation revealed two types of particles: one that contains no apoAl but apoE and another that contains no apoE but apoAI. These results show that several subfractions of lipoprotein particles exist in CSF, differing from each other in their combinations of apoE, apoJ, and apoAI. We concluded that there are at least 9 forms or combinations (including free apolipoproteins) of apoJ, apoE, and apoAl in the CSF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12458888

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  6 in total

Review 1.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

2.  Time-dependent decrease of clusterin as a potential cerebrospinal fluid biomarker for drug-resistant epilepsy.

Authors:  Weihua Yu; Dan Chen; Zhihua Wang; Chunlei Zhou; Jing Luo; Yali Xu; Lan Shen; Huan Yin; Shuxin Tao; Zheng Xiao; Fei Xiao; Yang Lü; Xuefeng Wang
Journal:  J Mol Neurosci       Date:  2014-02-02       Impact factor: 3.444

3.  Apolipoproteins in the brain: implications for neurological and psychiatric disorders.

Authors:  David A Elliott; Cyndi Shannon Weickert; Brett Garner
Journal:  Clin Lipidol       Date:  2010-08-01

4.  Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease.

Authors:  Yue Yang; C Dirk Keene; Elaine R Peskind; Douglas R Galasko; Shu-Ching Hu; Eiron Cudaback; Angela M Wilson; Ge Li; Chang-En Yu; Kathleen S Montine; Jing Zhang; Geoffrey S Baird; Bradley T Hyman; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2015-07       Impact factor: 3.685

Review 5.  Exploring the Role of CLU in the Pathogenesis of Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Mst Marium Begum; Md Siddiqul Islam; Tapan Behl; Ghulam Md Ashraf
Journal:  Neurotox Res       Date:  2020-08-21       Impact factor: 3.911

6.  Correlates and Predictors of Cerebrospinal Fluid Cholesterol Efflux Capacity from Neural Cells, a Family of Biomarkers for Cholesterol Epidemiology in Alzheimer's Disease.

Authors:  Eleonora Cipollari; Hannah J Szapary; Antonino Picataggi; Jeffrey T Billheimer; Catherine A Lyssenko; Gui-Shuang Ying; Leslie M Shaw; Mitchel A Kling; Rima Kaddurah-Daouk; Daniel J Rader; Domenico Praticò; Nicholas N Lyssenko
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.160

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.